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Abstract
 
Aspirin (ASA) is unique among current therapies because it acetylates cyclooxygenase (COX)-2
enabling the biosynthesis of 
 
R-
 
containing precursors of endogenous antiinflammatory media-
tors. Here, we report that lipidomic analysis of exudates obtained in the resolution phase from
mice treated with ASA and docosahexaenoic acid (DHA) (C22:6) produce a novel family of
bioactive 17
 
R
 
-hydroxy-containing di- and tri-hydroxy-docosanoids termed resolvins. Murine
brain treated with aspirin produced endogenous 17
 
R
 
-hydroxydocosahexaenoic acid as did hu-
man microglial cells. Human COX-2 converted DHA to 13-hydroxy-DHA that switched
with ASA to 17
 
R
 
-HDHA that also proved a major route in hypoxic endothelial cells. Human
neutrophils transformed COX-2-ASA–derived 17
 
R
 
-hydroxy-DHA into two sets of novel di-
and trihydroxy products; one initiated via oxygenation at carbon 7 and the other at carbon 4.
 
These compounds inhibited (IC
 
50
 
 
 
 
 
50 pM) microglial cell cytokine expression and in vivo
dermal inflammation and peritonitis at ng doses, reducing 40–80% leukocytic exudates. These
results indicate that exudates, vascular, leukocytes and neural cells treated with aspirin convert
DHA to novel 17
 
R
 
-hydroxy series of docosanoids that are potent regulators. These biosyn-
thetic pathways utilize omega-3 DHA and EPA during multicellular events in resolution to
produce a family of protective compounds, i.e., resolvins, that enhance proresolution status.
Key words: endothelial cells • leukocytes • docosahexaenoic acid • cyclooxygenase-2 • 
resolution
 
Introduction
 
The roles of eicosanoids in diverse physiologic and patho-
logic scenarios provide clear examples of the importance of
fatty acid precursors such as arachidonic acid in cell com-
munication, a sharp departure from their structural and
storage assignments (1–5). Among the classes of bioactive
eicosanoids, including prostaglandins, leukotrienes (LTs)
 
*
 
,
lipoxins (LX), and cis-epoxyeicosatrienoic acids or EETs
(4, 6), it is now apparent that counterregulatory autacoids
exist within these classes of eicosanoids. Of the cyclooxy-
genase pathways, prostacyclin and thromboxane are impor-
tant vascular counterregulators (7). In inflammation, LT
products of the 5-lipoxygenase (LO) are proinflammatory
mediators (4, 8), and LXs generated via LO interactions can
counterregulate certain LT-mediated events (for a review,
see reference 9). The emergence of temporal and spatial
separation in biosynthesis of eicosanoids during inflamma-
tion sheds light on distinct functional settings for LXs as
“stop” or proresolution signals (10). Moreover, aspirin
(ASA) treatment can pirate the LX system, triggering for-
mation of their 15-epimeric or their 
 
R
 
-containing isoform
(ASA-triggered LX) that serve as LX mimetics, to mount
proresolution status (9, 11, 12), as well as enhancers in epi-
thelial-based antimicrobial host defense (13).
Leukocytes from several species of fish rich in omega-3
fatty acids generate prostaglandins, LTs, and LXs from both
arachidonic acid (C20:4) and eicosapentaenoic acid (EPA)
(C20:5). Their immune functions in marine organisms
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appear similar to those in humans; namely, as drivers of cell
motility. Yet, fish cells generate quantitatively similar levels
of both 4 and 5 series (EPA-derived) LTs and LXs, which
is sharply different than human tissues that use predomi-
nantly C20:4-derived mediators (for a review, see reference
14). An extensive literature, accrued for several decades,
implicates omega-3 fatty acids such as EPA (C20:5) and
docosahexaenoic acid (DHA, C22:6) as beneficial in several
human diseases including atherosclerosis, asthma, cardio-
vascular, cancer (for a review, see reference 15), and, more
recently, mental depression (16, 17) and preventing sudden
death after myocardial infarction (18, 19). Of interest are
results from the GISSI-Prevenzione trial that evaluated
omega-3 polyunsaturated fatty acid (PUFA) supplementa-
tion with 
 
 
 
11,300 patients that provide compelling evi-
dence for a decrease of 
 
 
 
45% in cardiovascular death (20).
It is noteworthy that both patient groups received aspirin in
the GISSI trial while comparing tocopherol versus omega-3
supplementation (20) as did a significant number of par-
ticipants in the most recent Physician Health study report
(18). The impact of ASA to the results of these studies was
not tested although firmly concluding the benefits of
omega-3 fatty acids in risk reduction (18, 20, 21). Eating
fish rich in omega-3s is now recommended by the
American Heart Association (see http://www.american-
heart.org). However, what is evident from animal studies is
that DHA is the bioactive cardiovascular protective compo-
nent of fish oils (22). The mechanism(s) for omega-3 pro-
tective properties in heart disease and in prostate cancer re-
mains unclear and the molecular bases are still sought to
explain the clinical phenomena associated with fish oil trials.
The heightened awareness that unresolved inflammation
is important in many chronic disorders including heart dis-
ease, atherosclerosis, asthma, and Alzheimer’s disease (23,
24) leads us to question whether omega-3 utilization dur-
ing ASA therapy is converted to endogenous bioactive
compounds relevant in human disease and health. Re-
cently, we uncovered that at sites of inflammation omega-3
PUFA EPA is converted to potent bioactive products that
target neutrophil recruitment (2). Hence, cyclooxygenase
(COX)–2, which has a larger substrate tunnel/channel than
COX-1 (25, 26), acts on C20:4 as well as additional sub-
strates that can be productively accommodated as exempli-
fied by the ability to convert the omega-3 polyene family
of lipids (i.e., C18:3 and C20:5), possibly for tissue-specific
COX-2 missions (2) such as those associated with ischemic
preconditioning (19), resolution (10, 12, 27), and/or other
disease processes. Our recent results with EPA and COX-2
(2) as well as earlier findings of others with DHA (28–32)
raise the possibility that, in addition to arachidonic acid,
omega-3 fatty acids in certain biologic processes, e.g., isch-
emia-induced cardiac arrhythmias (22), may serve as sub-
strates for conversion to potent bioactive products (2).
However, the biological role and significance of products
that could be derived from DHA in inflammation has re-
mained to be established.
In this report, we demonstrate that ASA treatment of
murine in vivo and human tissues in vitro carrying COX-2
 
initiates the production of novel 17
 
R
 
-hydroxy series
docosanoids via previously undescribed biosynthetic cir-
cuits that counterregulate proinflammatory responses (i.e.,
cytokine production, peritonitis). During stress, these cel-
lular pathways utilize omega-3 fatty acids to biosynthesize
endogenous compounds that serve in antiinflammation sig-
naling. Thus, we termed the family of compounds Re-
solvins because they are (i) generated during the resolution
phase and (ii) chemically redundant signals that play protec-
tive roles in dampening inflammation to promote a prores-
olution status.
 
Materials and Methods
 
Zymosan A, hematin, NADPH, 15-LO, ASA, and other
NSAIDs were from Sigma-Aldrich. Potato 5-LO, DHA, and
EPA were from Cayman Chemical Co.; other synthetic stan-
dards, hydroxy fatty acids and intermediates used for MS identifi-
cation and fragment ion references were purchased from Cascade
Biochem Ltd. Authentic standards for 4
 
S
 
-hydroxy-5
 
E
 
, 7
 
Z
 
, 10
 
Z
 
,
13
 
Z
 
, 16
 
Z
 
, 19
 
Z
 
-DHA (4
 
S
 
-HDHA), 17
 
S
 
-hydroxy-4
 
Z
 
, 7
 
Z
 
, 10
 
Z
 
,
13
 
Z
 
, 15
 
E
 
, 19
 
Z
 
-DHA (17
 
S
 
-HDHA), and the racemate 17
 
R/S
 
-
hydroxy-4
 
Z
 
, 7
 
Z
 
, 10
 
Z
 
, 13
 
Z
 
, 15
 
E
 
, 19
 
Z
 
-DHA (denoted 17
 
R/S
 
-
HDHA) were from Penn Bio-Organics, and NMR analyses es-
tablished the respective double bond configurations. Additional
materials used in LC-MS-MS analyses were from vendors re-
ported in references (2, 33).
 
Incubations.
 
Human PMNs were freshly isolated from venous
blood of healthy volunteers (that declined taking medication for
 
 
 
2 wk before donation; BWH protocol no. 88–02642) by Ficoll
gradient and enumerated. Cells were divided into 50 
 
 
 
 10
 
6
 
 cells,
1 ml DPBS with Ca
 
2
 
 
 
 and Mg
 
2
 
 
 
, denoted 
 
 
 
/
 
 
 
, and incubations
(40 min, 37
 
 
 
C) were performed with either 17
 
R/S
 
-HDHA
(Penn Bio-Organics) or 17
 
R
 
-HDHA with zymosan A (100 ng/
ml; Sigma-Aldrich). Human umbilical vein endothelial cells
(HUVECs) or human microvascular endothelial cells (HMVECs;
Cascade Biologics) were cultured for transendothelial migration
(34) and incubations with HMVEC monolayers (1, 2, or 3 pas-
sages) seeded (
 
 
 
2 
 
 
 
 10
 
5
 
 cells/cm
 
2
 
) on polycarbonate permeable
supports precoated with 0.1% gelatin for ASA and DHA. For hy-
poxia experiments, plates of HUVECs treated with TNF-
 
 
 
 and
IL-1
 
 
 
 (both 1 ng/ml) were placed in a hypoxic chamber (3 h,
37
 
 
 
C) and returned to normoxia (21 h, 37
 
 
 
C). Next, ASA (500
 
 
 
M, 30 min) was added followed by DHA (
 
 
 
5 
 
 
 
M) and
A23187 (2 
 
 
 
M; 60 min, 37
 
 
 
C). Individual whole brains were
rapidly isolated from killed mice immediately before incubations
(each half/2 ml), washed with cold DPBS
 
 
 
/
 
 
 
 and incubated with
ASA (45 min, 37
 
 
 
C, 500 
 
 
 
M). Incubations were stopped with 5
ml cold methanol, and held at 
 
 
 
20
 
 
 
C for analyses.
 
Recombinant COX-2 and Product Analyses.
 
Human recombi-
nant COX-2 was overexpressed in 
 
Sf
 
9 insect cells (American
Type Culture Collection). The microsomal fractions (
 
 
 
8 
 
 
 
l)
were suspended in Tris (100 mM, pH 8.0) as in reference 35.
ASA was incubated (
 
 
 
2 mM, 37
 
 
 
C, 30 min) with COX-2 before
addition of DHA (10 
 
 
 
M), or in some experiments [1-
 
14
 
C]-
labeled DHA (American Radiolabeled Chemicals, Inc.), and con-
versions were monitored in parallel using [1-
 
14
 
C]-labeled C20:4
(with ASA) (as in Fig. 2; also see text).
Incubations were extracted with deuterium-labeled internal
standards (15-HETE and C20:4) for LC-MS-MS analysis as in
reference 33 using a Finnigan LCQ liquid chromatography ion
trap tandem mass spectrometer equipped with a LUNA C18–2 
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(150 
 
 
 
 2 mm 
 
 
 
 5 
 
 
 
m or 100 
 
 
 
 2 mm 
 
 
 
 5 
 
 
 
m) column and a
rapid spectra scanning UV diode array detector that monitored
UV absorbance 
 
 
 
0.2 min before samples entering the MS-MS.
All intact cell incubations and in vivo exudates were stopped with
2 ml cold methanol and kept at 
 
 
 
80
 
 
 
C for 
 
 
 
30 min. Samples
were extracted using C18 solid phase extraction and analyzed us-
ing gas chromatography-mass spectrometry (GC-MS) (see Table
II; Hewlett-Packard), thin layer chromatography or tandem liq-
uid chromatography-mass spectrometry (LC-MS-MS). Also, a
Chiralcel OB-H column (4.6 
 
 
 
 250 mm; J.T. Baker, Inc., Phil-
lipsburg, NJ) was used to determine 
 
R
 
 and 
 
S
 
 alcohol configura-
tions of monohydroxy-PUFA using isocratic mobile phase (hex-
ane:isopropanol; 97.5:2.5, vol:vol, with a 0.6 ml/min flow rate).
Detailed procedures for isolation, quantitation, and structural de-
termination of lipid-derived mediators were reported recently
(36) and used here essentially as reported for elucidation of novel
products. Biogenic synthesis of the novel docosanoids were per-
formed using isolated enzymes, i.e., potato 5-LO, rhCOX-2, or
ASA treated rhCOX-2 and 15–LO each incubated in tandem se-
quential reactions with either DHA or 17
 
R
 
-HDHA to produce
the novel compounds in scale up quantities for isolation and con-
firmation of physical and biological properties.
 
PMN Migration, Murine Air Pouch Exudates, and Peritonitis.
 
Human PMN transendothelial migration was quantitated by
monitoring myeloperoxidase an azurophilic granule marker as in
(34, 37).
 
 
 
Inflammatory exudates were initiated with intrapouch
injection of recombinant mouse TNF-
 
 
 
 (100 ng/pouch; R&D
Systems) into dorsal air pouches (10) of 6–8 wk male FVB mice
fed laboratory rodent diet 5001 (Lab Diet, Purina Mills) contain-
ing 
 
 
 
0.25% arachidonic acid, 1.49% EPA, and 1.86% DHA fol-
lowed by 500 
 
 
 
g ASA at 3.5 h and 300 
 
 
 
g DHA/pouch at 4 h
after TNF-
 
 
 
 injection. At 6 h (within the resolution phase),
pouches were lavaged (3 ml saline) and exudate cells were enu-
merated. Inhibition of TNF-
 
 
 
 stimulated (100 ng/pouch) PMN
infiltration with intravenous tail injection of either 17
 
R
 
-HDHA
(as prepared with COX-2 vide infra), 5S,12,18
 
R
 
-HEPE, or a 15-
epi-LXA
 
4
 
 analogue were determined with pouch lavages taken at
4 h. Peritonitis was performed using 6–8-wk-old FVB male mice
(Charles River Laboratories) fed laboratory Rodent Diet 5001
(Purina Mills) that were anesthetized with isoflurane, and com-
pounds to be tested (125 
 
 
 
l) were administered intravenously.
Zymosan A in 1 ml (1 mg/ml) was injected 
 
 
 
1–1.5 min later in
the peritoneum. Each test compound (100 ng/incubation, i.e.,
17R-HDHA in ethanol) or vehicle alone was suspended in 
 
 
 
5
 
 
 
l and mixed in sterile saline 120 
 
 
 
l. 2 h after the intraperitoneal
injections, and in accordance with the Harvard Medical Area
Standing Committee on Animals protocol no. 02570, mice were
killed and peritoneal lavages rapidly collected for enumeration.
 
Cell Culture.
 
Human glioma cells DBTRG-05MG cells
(American Type Culture Collection) were cultured as recom-
mended by American Type Culture Collection. For analyses, 10 
 
 
 
10
 
6
 
 cells per well in 6-well plates (Falcon) were stimulated for
16 h with 50 ng/ml of human recombinant TNF-
 
 
 
 (GIBCO
BRL) in the presence of specified concentrations of test com-
pounds (i.e.,17
 
R-HDHA) or vehicle (0.04% ethanol). Cells were
washed in DPBS /  and harvested in 1 ml of Trizol (GIBCO
BRL). For RT-PCR, RNA purification and RT-PCR were
performed as in reference 38. Primers used in amplifications were:
5 GGAAGATGCTGGTTCCCTGC3  and 5 CAACACGCA-
GGACAGGTACA3  for IL-1 ; 5 TCCACCACCGTGTTG-
CTGTAG3 ; and 5 GACCACAGTCCATGACATCACT3  for
GAPDH. PCR products obtained with these primers were con-
firmed by sequencing. Analyses were performed for both genes
(i.e., GAPDH and IL-1 ) in the linear range of the reaction. Re-
sults were analyzed using the NIH Image program (http://
rsb.info.nih.gov/nih-image).
Results
Lipidomics of the Exudate Resolution Phase. It is well ap-
preciated that orderly resolution in healthy individuals is
influenced by both systemic and local host factors that in-
clude nutrition, metabolic status (i.e., diabetes is associated
with delayed healing) and circulatory status as some of the
key determinants in the duration of resolution (39). In ex-
perimental acute inflammatory challenge that undergoes
spontaneous resolution, namely in the murine air pouch
model of exudate formation and resolution, we found a
temporal dissociation between the formation and actions of
local chemical mediators (10). LTs and prostaglandins are
generated rapidly and appear with leukocyte recruitment to
the air pouch exudate in line with their known actions as
proinflammatory mediators. LX biosynthesis concurs with
spontaneous resolution and the loss of PMN from the mu-
rine air pouch exudate, providing evidence that function-
ally distinct lipid mediator profiles switch from proinflam-
matory to antiinflammatory mediators such as LXs during
resolution (10).
Recently, we found that EPA is transformed in murine
exudates treated with ASA to novel products that possess
antiinflammatory properties, providing a potential mecha-
nism for omega-3 beneficial actions in many diseases (2).
Since DHA is cardioprotective (22), abundant in brain and
retina, and displays an impact in many physiologic pro-
cesses (28–32), lipidomic analyses were undertaken to de-
termine whether inflammatory exudates utilize DHA in the
resolution phase with ASA treatment.
Inflammatory exudates obtained within the resolution
phase formed within dorsal skin air pouches after injection
of TNF- , DHA, and aspirin treatment contained several
previously undescribed compounds revealed with LC-MS-
MS analysis (Fig. 1). It is noteworthy that the Lab Diet
5001 used to feed these mice contained 1.86% DHA and
1.49% EPA with  0.25% arachidonic acid (Purina Mills).
Additional mass spectral analysis using both GC-MS (with
derivatized products) and liquid chromatography-UV
diode array detector-tandem mass spectrometry (LC-UV-
MS-MS)-based analyses (which did not require derivatiza-
tion) indicated that the inflammatory exudate-derived ma-
terials contained novel hydroxy acids produced from both
DHA and EPA, namely these products were not present in
our database of properties of reported lipid mediators. The
EPA-derived products were established recently (2). Se-
lected ion chromatograms and MS-MS from results ac-
quired at m/z 343 were consistent with the production of
17-HDHA (Fig. 1, A and B), with lesser amounts of 7S-
and 4S-HDHA (Fig. 1 A) within the exudates. These
products coeluted with authentic 17(R/S racemic)-HDHA
and 4S-HDHA (qualified by NMR; see Materials and
Methods) in three different chromatographic systems (un-
published data), and their basic structural properties were1028 Endogenous Mediators of Antiinflammation in Exudates and Brain
consistent with those of related DHA-derived products
(28–30). ASA-treatment also gave novel di- and tri-
hydroxy products carrying the DHA backbone within the
inflammatory exudates; at this dose ASA completely inhib-
ited the in vivo production of thromboxane and pros-
tanoids. Importantly, ASA treatment in vivo and COX-2
gave previously unknown products from DHA that possess
bioactive properties (vide infra).
Results in Fig. 1 C show the MS-MS spectra of a dihy-
droxy-containing DHA with fragment ions consistent with
the structure shown in the inset, namely 7,17-diHDHA;
m/z 359 [M-H], m/z 341 [M-H-H2O], m/z 323 [M-H-
2H2O], m/z 315 [M-H-CO2], and m/z 297 [M-H-CO2-
H2O]. Additional diagnostic ions consistent with the 7-
and 17-hydroxy-containing positions were present at m/z
261, 247, and 217. A representative of the several novel tri-
hydroxy-containing DHA-derived compounds also present
in inflammatory exudates is shown in Fig. 1 D. Ions present
were consistent with its [M-H]   m/z 375, 357 [M-H-
H2O], 339 [M-H-2H2O], 331 [M-H-CO2], 313 [M-H-
CO2-H2O], 306, 303, 276, 273, 255 [273-H2O], 210, 195,
and 180. These physical properties (i.e., MS-MS, UV, LC
retention time) were entered into our database and used
throughout to identify these and related compounds and
to assess their bioimpact. These compounds were
deemed of interest because transfer of materials extracted
from inflammatory exudates in DHA plus ASA pouches
to naive mouse (intravenous or via intraperitoneal ad-
ministration) sharply reduced zymosan-induced PMN in-
filtration by  60%, indicating the in vivo utilization of
DHA and production of bioactive products within exu-
dates (vide infra).
The Role of COX-2 and ASA in Biosynthesis of R-contain-
ing HDHA. Chirality of the alcohol group at carbon-17
(Fig. 1 B) was established for the product that matched ex-
udate-derived 17-HDHA using a chiral HPLC column.
The alcohol at carbon 17 position proved to be predomi-
nantly in the R configuration ( 95%; n   4), indicating
that this was indeed a novel product of enzymatic origin
formed in vivo that was not known earlier. For example,
17S-HDHA is generated via 15-lipoxygenation or via au-
tooxidation in racemic  50:50 ratio of R/S mixtures (40,
41). Hence, the presence of the alcohol group in the R
configuration as 17R-HDHA from exudates (Fig. 1) was
indicative of an enzymatic origin. The substrate channel of
COX-2 is larger than COX-1 (26), suggesting the possibil-
ity of substrates larger than arachidonic acid. Consistent
with this, DHA was transformed by rhCOX-2 to 13-
HDHA (Fig. 2, left). The MS-MS obtained were consis-
tent with oxygen addition at the 13 position (i.e., m/z 193
and m/z 221) and, when COX-2 was treated with aspirin
to acetylate serine within the catalytic site (1, 26, 42), DHA
was enzymatically converted to 17R-HDHA (Fig. 2, right).
The MS-MS and diagnostic ions at m/z 343 [M-H], 325
[M-H-H2O], 299 [M-H-CO2], 281 [M-H-H2O-CO2],
245 and 274 consistent with 17-carbon alcohol group and
chiral analysis using chiral HPLC with reference materials
(Materials and Methods) indicated that the conversion of
DHA by aspirin-acetylated COX-2 yielded predominantly
( 98%) 17R-HDHA. The product of COX-2 matched
Figure 1. Inflammatory exu-
dates from mice treated with
ASA generate novel compounds:
LC-MS-MS-based lipodomic
analysis. (A) TNF- –induced leu-
kocyte exudates from dorsal air
pouches. Samples were collected
at 6 h from FVB mice given ASA
and DHA (Materials and Meth-
ods). Selected ion chromatogram
(m/z 343) showing the produc-
tion of 17R-HDHA, 7S-HDHA,
and 4S-HDHA. Using the diene
UV chromophores for quantita-
tion, 7-HDHA was  15% of the
exudate materials and was identi-
fied using a SIM trace for m/z
141 with ms/ms 343. In some
exudates 17S-HDHA was also
present from LO-dependent
routes (see text). MS-MS for B:
17R-HDHA (m/z 343); C:
7S,17R-diHDHA (m/z 359);
and D: 4,11,17R-triHDHA (m/z
375). See text for diagnostic
ions. Results are representative
of n   7.1029 Serhan et al.
the physical properties of the dominant 17-hydroxy–con-
taining DHA-derived compound identified in inflamma-
tory exudates (Fig. 1) in vivo with aspirin treatment. Un-
like COX-1, shown earlier not to convert DHA (43),
results with recombinant COX-2 in Table I and Fig. 2 in-
dicate that aspirin treatment of this enzyme generates pre-
dominantly 17R-HDHA. Other commonly used non-
steroidal antiinflammatory drugs, i.e., indomethacin,
acetaminophen, or the COX-2 inhibitor (e.g., NS-398),
did not give appreciable amounts of 17R-HDHA. Treat-
ment with aspirin gave a reciprocal relationship between 17-
versus 13-position oxygenation. Also in these incubations,
indomethacin, acetaminophen, and NS-398 each reduced
the overall oxygenation of DHA (to 13- as well as 17-
HDHA; Table I), but did not share the ability of ASA to
produce 17R-HDHA. For direct comparison, conversion
of C20:4 by ASA-acetylated COX-2 to 15R–HETE (67  
5% substrate conversion; n   3) was monitored in parallel
with the conversion of DHA to 17R-HDHA (52   3%;
mean   SEM; n   3).
Brain and Vascular Biosynthesis of the New Compounds.
In brain, COX-2 is present in constitutive as well as in in-
ducible pool(s) (28, 44). Results in Fig. 3, A and B indicate
that ASA-treated brain contained 17R-HDHA produced
from the endogenous sources of DHA. To address the pos-
sible cell types involved in 17R-HDHA generation in
brain, human microglial cells were exposed to TNF- ,
which upregulated expression of COX-2, followed by
treatment with ASA and the agonist ionophore A23187.
Human microglial cells generated 17R-HDHA in an ASA-
dependent fashion (Fig. 3 C). Hypoxia is also known to in-
duce COX-2 (45), and hypoxic endothelial cells exposed
to cytokine IL-1 , as endothelial cells might encounter at
inflammatory loci or with ischemic events (23), treated
with aspirin were a source of 17R-HDHA (Fig. 4).
Of interest, in the absence of ASA treatment, 17S-
HDHA and corresponding 17S-hydroxy-containing diHDHA
and triHDHA were products in murine exudates and hu-
man cells. Their formation differs from the present bio-
synthesis in that, rather than COX-2-ASA, 15-LO ini-
tiates biosynthesis in sequential lipoxygenation reactions to
produce di- and trihydroxy-DHA (i.e., 7S,17S-diHDHA,
10,17S-diHDHA, 4S,17S-diHDHA, 4S,11,17S-triHDHA
and 7S,8,17S-triHDHA; Table II) via epoxide intermedi-
ates. The biosynthesis of these 17S-containing epimers and
their actions will be reported elsewhere.
Bioactions of the New Compounds. Since microglial cells
are involved in host defense and inflammation in neural tis-
sues, we incubated human microglial cells with the COX-2
products 13- and 17R-HDHA (each at 100 nM) to deter-
mine if they had an impact on the generation of inflamma-
tory mediators (Fig. 5 A, inset). At nM concentrations, these
novel cyclooxygenase-2 products inhibit TNF- -induced
cytokine production with apparent IC50  50 pM, as did the
17-containing di- and trihydroxy-HDHA compound (Fig.
Figure 2. Novel ASA triggered HDHA products gener-
ated by human recombinant COX-2 ASA. 17R-HDHA.
Human recombinant COX-2 treated in the presence and
absence of 2 mM ASA was incubated with DHA (10  M,
30 min, 37 C). Incubations were stopped with 2 ml cold
methanol, extracted and taken for LC-MS-MS analyses.
Results are representative of incubations from more than
eight separate experiments, some with 1-14C-labeled
DHA. (Top) LC-MS-MS chromatogram of m/z 343
showing the presence of mono-HDHA. (Bottom) MS-MS
spectrum of (left) 13-HDHA without ASA treatment and
(right) 17R-HDHA with ASA treatment.
Table I. Impact of NSAIDs on COX-2 Conversion of DHA
NSAID
Percentage of
inhibition of
13-HDHA
Percentage of 
increase of
17-HDHA
%%
ASA 85.7   5.6 97.8   2.0
Indomethacin 89.8   0.5 0.0
Acetaminophen 87.7   4.3 0.0
NS398 (COX-2 inhibitor) 97.3   1.0 0.0
Results are the mean   SEM, n   3. Products were extracted, identified,
and quantitated using deuterium internal standards and LC-MS-MS
(Materials and Methods). NSAIDs were incubated 30 min with human
recombinant COX-2 (Materials and Methods). 2 mM ASA, 200 mM
indomethacin, 500 mM acetaminophen, and 100 mM NS398 were used.1030 Endogenous Mediators of Antiinflammation in Exudates and Brain
5 A). Next, the HDHA were tested for their ability to regu-
late transendothelial migration of human PMN. In the nM
range, neither of the COX-2–derived monohydroxy-DHA
products had a direct impact on PMN transmigration across
endothelial cell monolayers (Fig. 5 B). This finding contrasts
results obtained with both EPA- and arachidonic acid–
derived eicosanoid products that directly downregulate PMN
transmigration in vitro (2, 3). For purposes of direct com-
parison, results with an ASA-triggered EPA pathway prod-
uct 18R,5,12-triHEPE (P   0.01 by ANOVA) (2) were
compared with those obtained with 15-epi-16-para(fluoro)-
phenoxy-LXA4 (P   0.01 by ANOVA), a stable analogue
of ASA-triggered 15R-LXA4 produced with ASA treatment
from arachidonic acid (10, 37).
Biosynthesis of Novel Docosanoids by Human PMN: Cell–Cell
Interaction Products Matched in Exudates. Next, since PMNs
interact with vascular cells during inflammation (7), the
contribution of leukocytes was assessed in the production of
the novel di- and tri-hydroxy compounds present in inflam-
matory exudates (Fig. 1, A–D). To this end, human PMNs
were exposed to zymosan and 17R-HDHA produced via
ASA-treated COX-2 or endothelial cells. PMNs engaged in
phagocytosis transform 17R-HDHA to both di- and tri-
hydroxy-DHA (Fig. 6). The main conversions were to dioxy-
genation products including 7S,17R-diHDHA and 10,17R–
diHDHA with lesser amounts of 4S,17R-diHDHA as the
main dihydroxy–containing products present when moni-
tored at m/z 359 (Fig. 6). In addition, novel 17R-trihy-
droxy-containing products monitored at m/z 375 were
present including 4S,11,17R-triHDHA as well as a set of
trihydroxytetraene containing 7,8,17R-triHDHA (Table II).
These compounds formed by human PMN match those
produced within exudates generated in vivo in both their
chromatographic behavior and prominent ions present in
their respective mass spectra. LC-MS and on-line UV diode
array profiles shown in Fig. 7 from exudates of mice treated
with ASA indicate the in vivo production of both sets of
17R series di- and tri-hydroxy-containing products that
carry triene and tetraene chromophores (Table II). Sources
for these trihydroxy-DHA products as schematically illus-
trated include omega-1 hydroxylation at carbon 22 of either
7S,17R-diHDHA or 4S,17R-diHDHA via a p450-like re-
action (reference 6 and Fig. 8) that likely represents inactiva-
tion pathway products as with LTs such as formation of 20-
OH-LTB4, a product of omega-oxidation of LTB4 (2, 3, 6).
Transformation of 17R-HDHA by activated human
PMNs involved a 5-LO and an LTA4 synthase reaction that
Figure 3. Endogenous 17R-HDHA from brain and human microglial
cells treated with aspirin. (A) LC-MS-MS chromatogram obtained from
brain for relative abundance at m/z 327 for DHA and m/z 343 for the
monohydroxy product. (B) MS-MS spectrum of brain 17R-HDHA (m/z
343). Murine brain samples were incubated with ASA (45 min, 37 C).
Results are representative of n   6 mice treated with ASA versus five
mice without ASA. (C) Human microglial cells (HMG) treated with
ASA; MS-MS spectrum of HMG 17R-HDHA. 10   106 cells were ex-
posed to 50 ng/ml TNF-  and incubated (24 h, 37 C). Cells were treated
with ASA (500  M, 30 min, 37 C) followed by addition of ionophore
A23187 (5  M, 25–30 min). Incubations were stopped with MeOH, ex-
tracted and analyzed by tandem UV, LC-MS-MS (Fig. 3 inset shows
UV-chromatogram plotted at 235 nm absorbance) (n   4, d   20). Both
17R-HDHA and DHA were identified on the basis of individual reten-
tion times, parent ions, and daughter ions obtained.
Figure 4. Hypoxic HUVECs treated with ASA generate 17R-HDHA.
HUVECs were exposed to TNF-  and IL-1  (both 1 ng/ml) and placed
in a hypoxia chamber (3 h). The cells were treated with ASA (500  M,
30 min) followed by DHA (20  g/106 cells/10 ml plate) and A23187 (2
 M, 60 min). (A) LC-MS-MS chromatogram of ion m/z 343 shows the
presence of 17R-HDHA. (B) MS-MS spectrum (RT 21.2 min) of 17R-
HDHA identified by retention time, parent ions, and daughter ions and
matched with properties and authentic NMR qualified standard.1031 Serhan et al.
gave triHDHA products via the formation of respective 4S-
hydro(peroxy)-17R-hydroxy- and 7S-hydro(peroxy)-17R-
hydroxy-containing intermediates. Each was converted to
epoxide-containing intermediates, i.e., 4(5) epoxide or 7(8)
epoxide intermediates, that open via hydrolysis to give rise
to 4S,11,17R-triHDHA or in a parallel route to diols such
as the trihydroxytetraene set 7S,8,17R-triHDHA (Figs. 4,
7, and 8). The mechanism used by PMNs to convert the
17R-HDHA precursor appeared similar to that established
and identified for the epoxide generating capacity of the
human PMN 5-lipoxgenase, which performs both a lipoxy-
genation and epoxidation step (2, 4) as demonstrated with
the potato 5–LO (46). The conversion of 17R-HDHA by
human PMNs displayed similar features as those established
for the conversion of arachidonic acid to either LTB4 or
LXs as well as the recently uncovered 18R series of EPA
products (4, 9). We modeled these in vivo biosynthetic se-
quences of events using both plant (5-LO potato or 15-LO
soybean) and human enzymes added in tandem “one pot”
incubations that produce these compounds and matched
those of human PMNs and murine exudates (Materials and
Methods and Table II). Our findings with 17R-HDHA are
of interest because the S isomer 17S-HDHA, a product of
15-LO, can inhibit human neutrophil 5-LO production of
LTs from endogenous substrate (47). Along these lines,
we found that 17R-HDHA was converted by isolated po-
tato 5-LO to both 4S-hydro-(peroxy)-17R-hydroxy- and
7S-hydro-(peroxy)–17R-hydroxy-containing products that
were reduced to 4S,17R-diHDHA and 7S,17R-diHDHA,
respectively. These, as well as trihydroxy-DHA (see Table
II), are new products and indicate that 17R-HDHA is a
substrate for 5-LO and its epoxidase activity. The biogenic
synthesis and physical properties of the compounds pro-
duced (i.e., major ions of the methyl ester trimethylsilyl-
derivatives) with GC-MS analysis were consistent with the
fragments obtained without derivatization using LC-MS-
MS (Table II) and support the proposed structures as well as
was both the murine exudate and human PMN biosynthe-
sis from DHA (reference 29 for monohydroxy products).
Of interest, when added to human PMNs, 17R-HDHA
prevented formation of LTs both in vitro with human
PMNs and in murine exudates (n   4; data not shown).
Inhibition of PMN Recruitment in Peritonitis and Air Pouch:
Antiinflammatory Properties (Intravenous and Topical) of Re-
solvins. Although 17R-HDHA did not directly inhibit
neutrophil transmigration in vitro (Fig. 5 B), 17R-HDHA
did regulate in vivo PMN exudate cell numbers in perito-
nitis as well as in the dermal air pouch (Fig. 5 C). Also,
17R-HDHA was a potent inhibitor of zymosan-induced
peritonitis, as were both the di- and tri-hydroxy-contain-
ing compounds (i.e., 7S,17R-diHDHA and 4S,11,17R-tri-
HDHA). In addition to their ability to inhibit PMN re-
cruitment when injected i.v. within zymosan-induced
peritonitis, the 17R-hydroxy-HDHA-derived di- and tri-
hydroxy-containing products proved to be potent regula-
tors of leukocyte recruitment into the air pouch when ad-
ministered intravenously as well as topically with local
administration (Fig. 5 C). Thus, these results indicate that
human and murine leukocytes convert 17R-HDHA to a
novel series of 17R-hydroxy-containing di- and triHDHA;
namely, an ASA-triggered circuit to utilize DHA to pro-
duce a 17R-series of docosanoids (Fig. 8).
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Discussion
These results indicate that cells expressing COX-2 in
exudates and brain treated with ASA enzymatically trans-
form omega-3 DHA to previously unrecognized com-
pounds with bioactive properties in inflammation resolution,
i.e., a novel 17R series of hydroxy-DHAs. The ASA-
acetylated COX-2 present in these tissues generates pre-
dominantly 17R-HDHA that is converted further enzy-
matically to potent bioactive 17R series via lipoxygenation
and epoxidation in leukocytes to both di- and tri-hydroxy–
containing novel docosanoids (Fig. 8). DHA is the most
unsaturated of the omega-3 polyene family of fatty acids
Figure 5. Bioimpact properties of omega-3-
derived resolvins. (A) Human glioma cells: inhibition
of TNF-stimulated IL-1  transcripts. DBTRG-
05MG cells 106/ml were stimulated with 50 ng/ml
of human recombinant TNF-  for 16 h to induce
expression of IL-1  transcripts. Concentration de-
pendence with COX-2 products: 17-HDHA ( ),
13-HDHA ( ), and di-/tri-HDHA ( ). The IC50
for both compounds is  50 pM. (insets) Results
are representative of RT-PCR gels of MG cells ex-
posed to 100 nM of 13-HDHA or 17-HDHA and
graphed after normalization of the IL-1  transcripts
using GAPDH. n   2. (B) Influence of eicosanoids
and docosanoids on fMLP-induced neutrophil mi-
gration across microvascular endothelial monolayers.
Neutrophils (106 cells per monolayer) were ex-
posed to vehicle containing buffer, or indicated
concentrations of aspirin-triggered LXA4 analogue
(black diamonds) 5S,12,18R-triHEPE (black
squares), 17R-HDHA (black circles) or 13-HDHA
(black triangles) for 15 min at 37 C. Neutrophils
were then layered on HMVEC monolayers and
stimulated to transmigrate by a 10 8 M fMLP gra-
dient for 1 h at 37 C. Transmigration was assessed
by quantitation of the neutrophil marker myeloper-
oxidase. Results are presented as mean    SEM
number of PMNs (n   8–12 monolayers per con-
dition). (C) Reduction of PMN in murine perito-
nitis and skin pouch. Compounds (100 ng in 120
 l sterile saline) were injected by intravenous bolus
injection into the mouse tail vein and followed by
1 ml zymosan A (1 mg/ml) into the peritoneum.
Peritoneal lavages were collected (2 h) and cell
types were enumerated. Air pouch–compounds
(dissolved in 500  l of PBS without Ca2  or Mg2 )
injected into the air pouch via intrapouch injection
or via intravenous administration (in 120  l sterile
saline) followed by intrapouch injection of TNF- .
4 h later air pouch lavages were collected and cells
were enumerated and differentiated. Compounds
were prepared by biogenic synthesis or isolated
from in vivo exudates. The ratio of 7,17R-diHDHA
to 4,17R-diHDHA was  8:1; the ratio of
4,11,17R-triHDHA and 7,16,17R-triHDHA was  2:1; and the ratio of di- to triHDHA was  1:1.3. Exudate transfers to a native mouse (see text). ATL
denotes 15-epi-16-para(fluoro)-phenoxy-LXA4 (administered at 100 ng/mouse). Values represent mean   SEM from 3–4 different mice; *P   0.05
when infiltrated PMN is compared with vehicle control.
Figure 6. Resolvin production by human PMNs exposed to microbial
zymosan: novel 17R di- and triHDHA. Human PMNs (50   106 cells/
ml) incubated with zymosan A (100 ng/ml) and 17R-HDHA (5  g/ml,
40 min, 37 C). Results are representative of n   4.1033 Serhan et al.
in mammalian and fish tissues. In humans, DHA is abun-
dant in brain, retina, and testes (28, 48). The levels of
DHA increase in adult human brain with age, which is re-
quired for optimal neural development (49) and DHA is
rapidly esterified in retinal epithelium photoreceptors as
well as into the phospholipids of resting human neutrophils
(28, 50). At high micromolar values, DHA is held to pos-
sess both physiologic roles and direct action on neural volt-
age gated K  channels (51), binds RXR in neural tissues
(52) and is held to be the active compound of fish oil sup-
plements that is cardioprotective (21). Also, addition of
DHA can correct and reverse the pathology associated
with cystic fibrosis in cftr /  mice (53). However, it is not
clear from the results of these studies (21, 51, 52) or of the
many reported clinical trials whether DHA is precursor to
potent bioactive structures that are responsible for the
many reported properties attributed to DHA itself in regu-
lating biological systems of interest.
The three major LOs (i.e., 5-LO, 12-LO, and 15-LO)
that act on arachidonate can each convert DHA to S-con-
taining products, but their function in the immune system
or elsewhere is not clear. In the brain, 12-LO of pineal
body converts DHA to 14S-HDHA and 15-LO to 17S-
HDHA (40). DHA can also be converted by human neu-
trophils to 7S-HDHA that does not stimulate chemotaxis
(31), and retina converts DHA to both mono- and di-
hydroxy products via LO(s) (28). While not a substrate for
COX-1 (43), oxidized isoprostane-like compounds can
also be produced from DHA that appear to reflect oxida-
tive free radical catalyzed events (54). Hence, the new
17R-hydroxy series of docosanoids generated by neural tis-
sues, leukocytes, and inflammatory exudates uncovered in
these experiments and their role(s) are of interest in inflam-
mation resolution, a process now considered to be associ-
ated with many human diseases.
Figure 7. Inflammatory exudate produces 17R-containing di- and tri-
hydroxy tetraenes and triene-containing compounds: LC-MS-MS. See
Fig. 1 for details. Exudates were obtained and analyzed by procedures
essentially identical to those described in Fig. 1. (A) m/z were plotted at
375 (top), 359 (middle), and 343 (bottom). (B) UV absorbance was plotted
at 300 nm to mark tetraene-containing chromatophores. (C) MS-MS of
7S,8,17R-triHDHA.
Figure 8. Biosynthetic scheme
proposed for resolvins: aspirin-
triggered omega-3-derived
products. Acetylation of COX-2
by ASA treatment generates
novel 17R-H(p)DHA from
DHA that is reduced to its corre-
sponding alcohol and converted
via sequential actions of a leuko-
cyte 5–LO and leads to forma-
tion of both dihydroxy- and tri-
hydroxy-containing docosanoids
that retain their 17R configura-
tion. Pathways are denoted in
blue for omega oxidation prod-
ucts that are likely to be in vivo
markers of enzymatic inactiva-
tion. The resolvin pathways ap-
pear to be maximally induced
during the “spontaneous resolu-
tion” phase of inflammation and
compounds are activated to
dampen PMN infiltration, which
reduces exudate PMN numbers
to promote proresolution of in-
flammatory exudates (resolvins
from EPA, the 18R-HEPE se-
ries, are denoted in green) that
leads to potent inhibitors of
PMN recruitment in vitro and in
vivo (see pathway, right, text,
and reference 2). The complete stereochemistries of the new di- and tri-hydroxy–containing compounds remain to be established and are depicted here
in their likely configuration based on biogenic total synthesis. See Table II and text for further details.1034 Endogenous Mediators of Antiinflammation in Exudates and Brain
Although an extensive literature obtained with omega-3
fish oils encompassing both animal and human studies sug-
gests that EPA and DHA could have a beneficial impact in
the treatment of many chronic diseases (such as cardiovas-
cular disease, atherosclerosis, and asthma, as well as antitu-
mor and antiproliferative properties; references 15 and 55),
the molecular rationale for their use remains of interest.
Most of the earlier studies focused on uptake of omega-3
PUFA (i.e., EPA and DHA), namely their esterification
into phospholipid and other lipid stores of many human tis-
sues that in some cells reduces the availability of endoge-
nous arachidonic acid for processing to proinflammatory
prostaglandins (55). The body of results now available indi-
cates that, in addition to proinflammatory roles, specific 15-
LO, 5-LO, and/or LO-LO interaction products formed
during cell–cell interactions such as LXs serve as endoge-
nous antiinflammatory mediators promoting resolution (9,
10, 12). Like other LO-derived eicosanoids, LXs are po-
tent-local acting in subnanomolar levels with precise ste-
reochemical requirements for evoking their actions (4, 9).
Hence, the production of 18R and 15R series products
from EPA that inhibit PMN transmigration and inflamma-
tion within the low nanomolar range emphasizes the func-
tional redundancies within chemical mediators produced
from the omega-3 family of polyene fatty acids, namely the
recently identified compounds from COX-2 EPA (2) or
DHA-derived compounds as indicated from the present re-
sults (Figs. 6–8). It is important to note that with these
small molecular weight mediators subtle changes in chiral-
ity of alcohol-i.e., S to R–can change a compound from
active to inactive or vice versa (3, 4, 9). In this regard, the
15R-hydroxy-containing compounds generated from ei-
ther arachidonic acid or EPA and 18R series from EPA, as
well as 17R-hydroxy series from DHA, each display similar
functional redundancies in inflammation resolution. Hence,
uncovering the 17R series of both mono- and di-oxygen-
ation products in inflammatory exudates and a role for
COX-2 in the generation of the 17R-hydroxyl configura-
tion in HDHA described here for the first time opens new
avenues for considering the overall functional redundancies
of mediators that dampen and/or counter the many proin-
flammatory signals to promote resolution.
COX-2 is induced in most inflammatory cell types, but
can also be constitutive in neural and vascular tissue (44,
56). The importance of the enlarged substrate tunnel in
COX-2 becomes of interest when considering possible
physiologic roles of this enzyme in these localities in vivo.
It is now clear from numerous studies that aspirin has ben-
eficial effects in and apart from other nonsteroidal antiin-
flammatory drugs (57, 58). In this regard, ASA has a
unique ability to acetylate both isoforms of COX-1 and
COX-2. It is also noteworthy that DHA is cardioprotec-
tive in the ischemic heart (22) and that COX-2 is involved
in preconditioning (19) as well as resolution (12). Our
present results indicate that DHA is a precursor and is con-
verted to 17R-HDHA via ASA-acetylated COX-2 at sites
of inflammation in vivo (Fig. 1), murine brain (Fig. 3), and
by acetylated recombinant COX-2 in vitro (Fig. 2). Both
13- and 17R-HDHA inhibit cytokine generation by mi-
croglial cells at the transcript level in the picomolar range
(Fig. 5 A). Human microglial cells generate these 17R-
HDHA series products when given aspirin and TNF- ,
which upregulate COX-2 expression (Fig. 3 C). In addi-
tion, murine inflammatory exudates produced a family of
novel di- and tri-hydroxy products that were also pro-
duced by human PMN via transcellular processing of
17R-HDHA. The proposed pathways for transcellular pro-
cessing of acetylated COX-2–derived 17R-HDHA high-
lighting the generation of dioxygenated intermediates and
epoxidation to form novel diHDHA during vascular in-
flammation-associated events are illustrated in Fig. 8. It
should be noted that these and related structures can be
generated via cell–cell interactions or single cell types as
depicted in Fig. 8, but could in theory also be produced
via several sequential oxygenation routes by a single en-
zyme as well (see Fig. 8 legend). When these products
were prepared by biogenic total synthesis and added back
via topical administration into the air pouch, they inhibited
TNF- –induced leukocyte infiltration. Also, each mem-
ber of the pathway carried biological activity with in-
creased potencies as the di- and tri-hydroxy products
compared with the monohydroxy-containing products,
findings that suggest that activation of the entire pathway is
involved in evoking responses. Also, with intravenous ad-
ministration these compounds inhibited leukocyte recruit-
ment in both murine air pouch and in zymosan-induced
peritonitis (Fig. 5). Taken together, these results indicate
that ASA-acetylated COX-2–derived products can down-
regulate cytokine generation and leukocyte (i.e., neutro-
phil) recruitment to sites of inflammation. The EPA-
derived 5,12,18R series product proved to be as effective as
a potent stable analogue of 15-epi-LXA4 in preventing
leukocyte diapedesis and exudate formation (Fig. 5 C). For
comparison, both the EPA- and DHA-derived resolvins at
a 100 ng dose/mouse were more potent than indometha-
cin at an equal dose that gave  25% inhibition at 100 ng/
mouse or 3  g/kg in zymosan-induced peritonitis (n   3).
Since 17R-HDHA did not have a direct impact on human
PMN transmigration in these conditions, but reduced exu-
date PMN numbers in vivo as well as regulates gene ex-
pression in human microglial cells, it is highly likely that a
multilevel mechanism of action accounts for the in vivo
properties of this ASA-triggered pathway. Moreover, there
appear to be functional redundancies between the path-
ways in that the 18R series from EPA- and 17R series
DHA-derived hydroxy-containing compounds share in
their ability to regulate PMN exudate numbers (Fig. 5).
Emergence of the finding that arachidonic acid-derived
LXs inhibit PMN trafficking and serve as endogenous anti-
inflammatory mediators while activating monocytes in a
nonphlogistic fashion (11, 59), as well as accelerating the
uptake of apoptotic PMN by macrophages at sites of in-
flammation (28), indicates that not all LO pathway prod-
ucts from the arachidonic acid precursor are “pro”-inflam-
matory. Given their longer half-life and bioavailability, the
metabolically more stable analogs of these local-acting lipid1035 Serhan et al.
mediators derived from arachidonate in vivo and prepared
by total organic synthesis provide further evidence for their
roles in promoting resolution (37). Moreover, these results
suggest that the new resolving properties belong to a larger
class of endogenous compounds with mechanisms directed
toward enhancing resolution. Also, the link between anti-
inflammation and enhanced endogenous antimicrobial ac-
tivities (13) by LXs and ASA-triggered LXs sets a unique
precedent for the importance of cell–cell communication
and transcellular biosynthesis in host defense and in the
clearance and resolution of inflammatory sequelae. These
results disclosing 17R series oxygenated DHA products and
with the 15R and 18R series from EPA as prototypes (2),
taken together, suggest that the generation of local-acting
lipid mediators with beneficial actions relevant in human
disease may not be restricted to arachidonic acid alone as an
important precursor. Also, they indicate that transcellular
biosynthesis unveils previously unrecognized pathways that
are evoked by ASA treatment with DHA. Acetylated
COX-2 acts in an “R-oxygenation” mechanism to initiate
the conversion of DHA to a 17R series of di- and tri-
hydroxy docosanoids that display downregulatory actions
in vivo in inflammation as do the omega-3 EPA-derived
18R-series-products. Hence, it follows that once inflamma-
tion is initiated, upon ASA treatment with omega-3 sup-
plementation, these pathways can be operative in vascular
tissues to generate products that appear to have properties
as ASA-triggered lipid mediators similar to either the 15-
epi-LXs or 18R– and 15R series products from EPA. These
compounds are generated via lipoxygenation followed by
epoxidation and subsequent steps (Fig. 8 and reference 2).
Also of interest are our findings that, in the absence of
ASA, COX-2 converts DHA to 13-HDHA, a previously
unknown route that might also be relevant in tissues that
constitutively express COX-2, which is also converted to
dihydroxy DHA products (4,13-diHDHA, 7,13-diHDHA,
and 13,20-diHDHA), and during resolution, induction,
and conversion by 15-LO (10) to 10,17S-diHDHA and
7S,17S-diHDHA, the pathways and actions of which will
be reported elsewhere.
Since the properties of the omega-3–derived products
from acetylated COX-2 via transcellular biosynthesis ap-
pear to dampen events in inflammation apparently in a
functionally redundant fashion (i.e., 17R–HDHA series,
18R- and 15R-HEPA series), the term “resolvins” is in-
troduced for this family of new compounds and bioactions.
Resolvins, by definition, are endogenously generated
within the inflammatory resolution phase and downreg-
ulate leukocytic exudate cell numbers to prepare for or-
derly and timely resolution. These results indicate that the
17R series of di- and tri-hydroxy DHA pathways are po-
tent in models relevant in inflammation. It is likely that
these compounds will also have actions in other tissues, in
view of the many reports of the clinical actions for EPA
and DHA, where high concentrations of these PUFA are
used and required to evoke responses in vitro. Theses re-
sults indicate that cell–cell interactions at sites of inflam-
mation resolution utilize omega-3 fatty acids to generate
novel omega-3–derived products including 17R-HDHA
series and 18R-HEPE series of oxygenated bioactive
products termed resolvins (Fig. 8). Given their potent ac-
tions, the production of Resolvins may, in part, provide a
molecular rationale underlying the beneficial actions of
omega-3 fatty acids (15–22) in neoplasia, chronic im-
mune, and cardiovascular diseases and serve as new
biotemplates for therapeutic development.
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